Egrifta (Tesamorelin) Compounding Pharmacy: 503A vs 503B

What Is Tesamorelin and Why Does Its Pharmacy Source Matter?

Tesamorelin is a synthetic 44-amino-acid analog of human GHRH. The FDA approved Egrifta (Theratechnologies) in November 2010 under NDA 022505 specifically to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy. [1] A higher-dose formulation, Egrifta SV (2 mg), received approval in 2019. [2]

Because the branded product is expensive, often exceeding $3,000 per month, and off-label demand has grown among patients seeking GH-axis optimization, compounding pharmacies began producing tesamorelin independently. That commercial reality creates a two-track supply chain, and each track carries different regulatory obligations and quality guarantees.

Why Pharmacy Classification Is Not a Technicality

The classification of a pharmacy as 503A or 503B is not administrative paperwork. It determines which federal agency has primary inspection authority, which sterility standards apply, whether the product requires a patient-specific prescription before compounding starts, and what batch-release testing the compounder must document. A patient receiving an injection from an uninspected facility is exposed to risks that go well beyond subpotent peptide.

The FDA has issued multiple warning letters to compounders of injectable peptides for failing basic sterility and labeling requirements. [3] Those letters are publicly searchable on the FDA's warning letter database and should be the first document a prescriber or patient reviews before selecting a pharmacy.

The 503A Framework: Patient-Specific Compounding

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA), a pharmacy may compound a drug product for an identified individual patient based on a valid prescription from a licensed practitioner. [4] State boards of pharmacy are the primary regulators, and the FDA generally defers to state oversight unless the product crosses state lines in large volumes.

What 503A Requires for Sterile Tesamorelin

Tesamorelin is administered by subcutaneous injection, which makes it a sterile preparation. Any 503A pharmacy compounding it must comply with USP <797>, the chapter that governs sterile compounding. [5] The 2023 revised USP <797> chapter, which became official on November 1, 2023, tightened beyond-use dating (BUD), environmental monitoring frequency, and personnel training requirements compared with the 2008 version. [5]

Key 503A sterility obligations for an injectable peptide like tesamorelin include:

• Sterility testing or, for shorter BUDs, reliance on ISO 5 (Class 100) cleanroom compounding conditions
• Endotoxin testing referenced against USP <85> limits
• Potency verification, though frequency requirements vary by state
• Proper cold-chain storage (tesamorelin is lyophilized and requires refrigeration at 2-8°C)

The Prescription Requirement and State Variation

A 503A pharmacy cannot legally compound tesamorelin "in anticipation" of prescriptions beyond a very small quantity. Every vial must trace to a named patient. Some state boards, including Texas, California, and Florida, conduct routine inspections of sterile compounders and publish compliance reports. A prescriber ordering from an out-of-state 503A pharmacy should verify that the pharmacy holds a non-resident pharmacy license in the patient's state. [4]

The 503B Framework: Outsourcing Facilities

Section 503B of the FDCA, added by the Drug Quality and Security Act (DQSA) of 2013, created a voluntary registration category called "outsourcing facilities." [6] A 503B facility may compound without patient-specific prescriptions and may sell in bulk to hospitals, clinics, and practitioners. In exchange, the facility accepts federal cGMP (current Good Manufacturing Practice) inspections by the FDA, not just state-board inspections.

How 503B Raises the Quality Floor

The cGMP framework applied to 503B facilities overlaps with pharmaceutical manufacturing standards. That means:

• Full batch records with in-process controls
• Certificate of Analysis (COA) for each lot, signed by a qualified person
• Validated HPLC assays for identity and potency
• Sterility and endotoxin testing on every production batch, not just periodic monitoring
• Stability data supporting labeled BUD

The FDA publishes a current list of registered 503B outsourcing facilities. [7] Before ordering tesamorelin from any 503B source, a clinic should confirm the facility appears on that list and review any inspection observations (Form 483s) posted on FDA's inspection database. [7]

503B and the Drug Shortage Pathway

One major legal consideration is that 503B facilities may compound copies of commercially available drugs only under specific conditions. The FDA's policy generally prohibits compounding copies of approved drugs unless the drug appears on the FDA's drug shortage list or the compounder can demonstrate a "clinical difference" for the patient. [8] As of early 2025, tesamorelin does not appear on FDA's drug shortage list. [8]

This means a 503B facility compounding tesamorelin is operating in regulatory gray territory unless it is compounding a variant with a documented clinical difference (for example, a different concentration for a patient unable to tolerate reconstitution volumes of the commercial product). Prescribers should request written documentation of the facility's legal rationale before purchasing.

Quality Standards: What to Test and What Numbers to Demand

Quality testing is where the practical difference between a trustworthy compounder and a dangerous one becomes measurable. A COA should not be the end of the conversation. Prescribers and patients should understand what each test means for tesamorelin specifically.

HPLC Purity and Peptide Identity

High-performance liquid chromatography (HPLC) is the standard analytical method for peptide purity. For therapeutic-grade compounded tesamorelin, a COA should show purity at or above 98% by HPLC, with no single impurity exceeding 0.5%. Mass spectrometry (MS) confirmation of molecular weight provides identity verification; tesamorelin has a molecular weight of approximately 5,135 daltons. If a COA lists only "purity by HPLC" without a chromatogram or without MS confirmation, that is an incomplete document.

A 2022 analysis published in the Journal of Pharmaceutical and Biomedical Analysis found that several commercially sourced "research peptides" tested well below labeled purity, with some samples containing related peptide fragments at concentrations high enough to alter bioactivity. [9] That finding is directly relevant to tesamorelin, which shares structural similarity with other GHRH analogs that could appear as impurities.

Sterility and Endotoxin Testing

Sterility testing per USP <71> requires incubation in two culture media for 14 days. A negative sterility test is necessary but not sufficient. Endotoxin testing per USP <85> (Limulus Amebocyte Lysate assay) must also be passed. The general FDA guidance for parenteral products sets a threshold of 5 EU/kg/hr for intravenous products; subcutaneous injectables typically apply a similar or slightly relaxed threshold, but the specific limit should appear in the product's specifications on the COA. [10]

Residual Solvents and Moisture Content

Lyophilized peptides can retain residual solvents from the manufacturing process. USP <467> governs acceptable residual solvent levels. Moisture content by Karl Fischer titration should be below 3% for lyophilized tesamorelin, as higher moisture accelerates degradation. A pharmacy that cannot provide these data on request is not operating at a standard compatible with patient safety.

Is Compounded Tesamorelin Legal?

The legality of compounded tesamorelin is nuanced. It is not on the FDA's list of drugs that may not be compounded (the "503A Bulks List" or "503B Bulks List"). [11] That means compounding is not categorically prohibited. The operative legal question is whether a given compounder is following the applicable rules for their pharmacy class.

For 503A Pharmacies

A licensed 503A pharmacy may compound tesamorelin for a specific patient with a valid prescription from a licensed prescriber, provided the pharmacy meets USP <797> and state board requirements. [4] The prescription must be for a legitimate medical purpose, and the prescriber should document clinical rationale, particularly since off-label use (i.e., for conditions other than HIV-associated lipodystrophy) requires a clear medical justification in the patient record.

For 503B Outsourcing Facilities

A registered 503B facility may compound tesamorelin only if it can establish a clinical difference from the commercially available product or if commercial supply is unavailable. [6] Given that Egrifta SV is commercially available as of 2025, a 503B facility compounding a straightforward copy carries regulatory risk and that risk transfers to the prescribing clinic.

Research-Grade Tesamorelin: A Clear Legal Line

Many websites sell tesamorelin labeled "for research use only" or "not for human use." The FDA has been explicit: labeling a drug "for research use only" does not exempt it from the FDCA's new drug provisions if the seller knows or should know it will be used in humans. [12] The FDA's 2022 guidance on research chemicals reinforced this position. [12] A physician who dispenses or administers research-grade peptides to patients may face state medical board discipline and federal prosecution.

PCAB Accreditation and What It Signals

The Pharmacy Compounding Accreditation Board (PCAB), now administered by URAC, offers voluntary accreditation for compounding pharmacies. PCAB accreditation requires on-site inspection and verification of compliance with USP <795>, USP <797>, and USP <800> (hazardous drugs). [13]

PCAB accreditation does not replace FDA oversight and does not guarantee the absence of errors. However, it does signal that a pharmacy has submitted to an independent third-party review of its sterile compounding practices. For a peptide like tesamorelin, where the cold chain, lyophilization, and reconstitution steps all create opportunities for quality failure, choosing a PCAB-accredited 503A pharmacy or a 503B facility with a clean FDA inspection record is the most defensible clinical decision.

The FDA's current list of 503B outsourcing facilities with inspection classifications is searchable at fda.gov. [7] Facilities with "Voluntary Action Indicated" (VAI) or "No Action Indicated" (NAI) classifications after their most recent inspection are preferable to those with "Official Action Indicated" (OAI) classifications, which signal significant compliance deficiencies.

Practical Buyer Guidance: A Step-by-Step Checklist

Selecting a pharmacy for compounded tesamorelin requires more than a price comparison. The following steps apply whether the ordering party is a telehealth clinic, a private practice, or an individual patient with a prescription.

Step 1: Confirm Pharmacy Registration and Licensure

Check the FDA's 503B outsourcing facility list (for bulk orders to clinics) or confirm 503A state licensure via the relevant state board. For out-of-state purchases, verify the pharmacy's non-resident pharmacy license in your state.

Step 2: Request a Current Certificate of Analysis

The COA should be batch-specific, dated within the last six months, and signed by a qualified laboratory director. It must include HPLC purity (≥98%), MS identity confirmation, sterility result (pass), endotoxin result with numeric value and limit, residual moisture, and labeled BUD with storage conditions.

Step 3: Verify Independent Third-Party Testing

The most reliable COAs come from ISO/IEC 17025-accredited third-party laboratories, not in-house testing by the compounding pharmacy itself. Ask specifically whether the testing laboratory is independent and accredited. Some pharmacies publish COA results from recognized laboratories such as Analytical Bio-Chemistry Laboratories (ABC Labs) or similar contract laboratories.

Step 4: Review FDA Warning Letters and Inspection History

Search the FDA warning letters database (fda.gov/inspections-compliance-enforcement) for the pharmacy name. [3] A warning letter within the last 24 months is a disqualifying signal for a sterile compounder unless the pharmacy can document that all cited deficiencies have been corrected and verified.

Step 5: Assess Cold-Chain Shipping Practices

Tesamorelin is a lyophilized powder requiring storage at 2-8°C (36-46°F). The reconstituted solution degrades at room temperature. A pharmacy that ships tesamorelin without validated cold-chain packaging (ice packs with temperature monitors) is not meeting basic stability requirements. Ask for the shipping validation protocol before placing an order.

Clinical Context: Off-Label Use and Prescriber Responsibility

The FDA-approved indication for tesamorelin is narrow: reduction of excess visceral abdominal fat in HIV-1-infected adults with lipodystrophy. [1] Two key trials, LIPO-010 and LIPO-011 (combined N=816), demonstrated statistically significant reductions in visceral adipose tissue (VAT) by dual-energy X-ray absorptiometry (DEXA) at 26 weeks, with a mean VAT reduction of approximately 18% versus placebo (P<0.0001). [14]

Off-label use for metabolic optimization, body composition in non-HIV populations, or GH-axis stimulation in aging adults is not supported by FDA-approved labeling. Prescribers who write tesamorelin prescriptions for off-label purposes carry the clinical and legal responsibility of documenting medical necessity, obtaining informed consent that describes off-label status, and monitoring appropriately. The Endocrine Society's 2019 clinical practice guidelines on growth hormone deficiency in adults do not include tesamorelin as a recommended therapeutic agent for that indication. [15]

What the HealthRX Medical Team Tells Patients

Our reviewing physicians advise every patient asking about compounded tesamorelin to request the COA before the first shipment arrives, not after. A pharmacy unwilling to provide a batch-specific COA with third-party lab data should be disqualified immediately. The COA is not optional documentation. It is the only evidence that what is in the vial matches what the label says.